MARKET

GPCR

GPCR

Structure Therapeutics Inc ADR
NASDAQ
53.45
+1.33
+2.55%
After Hours: 53.44 -0.01 -0.02% 19:45 07/02 EDT
OPEN
51.43
PREV CLOSE
52.12
HIGH
54.24
LOW
51.02
VOLUME
592.50K
TURNOVER
--
52 WEEK HIGH
94.90
52 WEEK LOW
15.80
MARKET CAP
3.80B
P/E (TTM)
-19.6284
1D
5D
1M
3M
1Y
5Y
1D
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
NASDAQ · 1d ago
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Seeking Alpha · 4d ago
Weekly Report: what happened at GPCR last week (0622-0626)?
Weekly Report · 5d ago
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
Benzinga · 06/22 11:15
Weekly Report: what happened at GPCR last week (0615-0619)?
Weekly Report · 06/22 09:10
Shareholders Approve Directors, Auditors at 2026 Meeting
TipRanks · 06/18 21:07
Structure Therapeutics shareholders elect directors at annual meeting
PUBT · 06/18 20:06
Weekly Report: what happened at GPCR last week (0608-0612)?
Weekly Report · 06/15 09:09
More
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Webull offers Structure Therapeutics Inc (ADR) stock information, including NASDAQ: GPCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GPCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GPCR stock methods without spending real money on the virtual paper trading platform.